Director Michael Bonney resigns from Bristol-Myers board to become Executive Chairman of Alnylam

BRISTOL MYERS SQUIBB CO

Bonney resigned effective August 3, 2021, in connection with his appointment as Executive Chairman of Alnylam Pharmaceuticals.
Board set number of directors at ten, down from the prior size (not specified).
No other changes to board composition or officer positions disclosed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Bonney

Director

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2021-08-03
Filed: August 9, 2021, 7:59 PM ET

On August 3, 2021, Mr. Michael Bonney resigned from the Board of Directors of Bristol-Myers Squibb Company in connection with his appointment as Executive Chairman of Alnylam Pharmaceuticals Inc .

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Bonney resigned as Director at BRISTOL MYERS SQUIBB CO.

Action: resigned
Role: Director

Exact text from the filing

On August 3, 2021, Mr. Michael Bonney resigned from the Board of Directors of Bristol-Myers Squibb Company in connection with his appointment as Executive Chairman of Alnylam Pharmaceuticals Inc .

View on SEC.gov

BRISTOL MYERS SQUIBB CO filing history →

Source: SEC EDGAR

accession 0001140361-21-027569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.